Posted by Michael Wonder on 08 Apr 2024
ARS Pharmaceuticals submits response to FDA complete response letter for neffy (epinephrine nasal spray)
3 April 2024 - Submission of complete response letter response triggers up to six month review period by the FDA.
ARS Pharmaceuticals announced today that it has submitted its response to the US FDA for its new drug application for neffy (epinephrine nasal spray), for the treatment of Type I allergic reactions including anaphylaxis.
